Published in Ann Rheum Dis on January 01, 2010
Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford) (2009) 2.35
Intrinsic gene expression subsets of diffuse cutaneous systemic sclerosis are stable in serial skin biopsies. J Invest Dermatol (2012) 1.91
Assessing microvascular changes in systemic sclerosis diagnosis and management. Nat Rev Rheumatol (2010) 1.64
B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial. Arthritis Res Ther (2010) 1.09
Immunotherapy of systemic sclerosis. Immunotherapy (2010) 1.03
The role of type 1 interferon in systemic sclerosis. Front Immunol (2013) 0.86
B-cell depletion therapy in patients with diffuse systemic sclerosis associates with a significant decrease in PDGFR expression and activation in spindle-like cells in the skin. Arthritis Res Ther (2012) 0.83
B-cell depletion therapy in systemic sclerosis: experimental rationale and update on clinical evidence. Int J Rheumatol (2011) 0.82
Efficacy and safety of rituximab in rheumatic diseases. Wien Med Wochenschr (2015) 0.81
B cells tell scleroderma fibroblasts to produce collagen. Arthritis Res Ther (2013) 0.79
Histopathological cutaneous alterations in systemic sclerosis: a clinicopathological study. Arthritis Res Ther (2011) 0.79
Targeted therapy for systemic sclerosis: how close are we? Nat Rev Rheumatol (2010) 0.78
Rituximab for refractory digital infarcts and ulcers in systemic sclerosis. Clin Rheumatol (2014) 0.78
Recent Treatments of Interstitial Lung Disease with Systemic Sclerosis. Clin Med Insights Circ Respir Pulm Med (2016) 0.78
Treatment of Rapidly Progressive Systemic Sclerosis: Current and Futures Perspectives. Expert Opin Orphan Drugs (2015) 0.77
Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study. Arthritis Res Ther (2016) 0.77
B cell block: is rituximab a new possible treatment for systemic sclerosis? J Cell Commun Signal (2010) 0.77
Assessment of liver stiffness in patients with HCV and mixed cryoglobulinemia undergoing rituximab treatment. J Transl Med (2014) 0.76
Scleroderma therapy: clinical overview of current trends and future perspective. Rheumatol Int (2012) 0.76
Rituximab in the treatment of systemic sclerosis-associated interstitial lung disease: comment on the article by Yoo. Rheumatol Int (2010) 0.75
B cell depletion therapy upregulates Dkk-1 skin expression in patients with systemic sclerosis: association with enhanced resolution of skin fibrosis. Arthritis Res Ther (2016) 0.75
Immune-regulatory mechanisms in systemic autoimmune and rheumatic diseases. Clin Dev Immunol (2011) 0.75
B-cell depletion with rituximab: a promising treatment for diffuse cutaneous systemic sclerosis. Arthritis Res Ther (2010) 0.75
B Cell Homeostasis and Functional Properties Are Altered in an Hypochlorous Acid-Induced Murine Model of Systemic Sclerosis. Front Immunol (2017) 0.75
Subclinical dermal involvement is detectable by high frequency ultrasound even in patients with limited cutaneous systemic sclerosis. Arthritis Res Ther (2017) 0.75
Current perspective on rituximab in rheumatic diseases. Drug Des Devel Ther (2017) 0.75
[Towards an implementation of guidelines for the therapy of systemic sclerosis (scleroderma): between desire and reality]. Z Rheumatol (2010) 0.75
Expression and regulation of the human beta-defensins hBD-1 and hBD-2 in intestinal epithelium. J Immunol (1999) 3.39
Glycolipid antigen processing for presentation by CD1d molecules. Science (2001) 3.04
Specific presence of intracellular citrullinated proteins in rheumatoid arthritis synovium: relevance to antifilaggrin autoantibodies. Arthritis Rheum (2001) 2.96
Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis. Ann Rheum Dis (2004) 2.18
Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations. Ann Rheum Dis (2004) 2.15
The evolution of spondyloarthropathies in relation to gut histology. II. Histological aspects. J Rheumatol (1995) 1.99
Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis (2000) 1.79
Repeated infusions of infliximab, a chimeric anti-TNFalpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow up. Ann Rheum Dis (2002) 1.76
Immunomodulatory effects of anti-tumor necrosis factor alpha therapy on synovium in spondylarthropathy: histologic findings in eight patients from an open-label pilot study. Arthritis Rheum (2001) 1.70
The evolution of spondyloarthropathies in relation to gut histology. III. Relation between gut and joint. J Rheumatol (1995) 1.51
Autologous matrix-induced chondrogenesis combined with platelet-rich plasma gel: technical description and a five pilot patients report. Knee Surg Sports Traumatol Arthrosc (2010) 1.51
Comparative study of the synovial histology in rheumatoid arthritis, spondyloarthropathy, and osteoarthritis: influence of disease duration and activity. Ann Rheum Dis (2000) 1.47
Human cartilage glycoprotein-39 as a candidate autoantigen in rheumatoid arthritis. Arthritis Rheum (1997) 1.46
The evolution of spondyloarthropathies in relation to gut histology. I. Clinical aspects. J Rheumatol (1995) 1.44
Tuberculin skin test versus interferon-gamma release assays for the diagnosis of tuberculosis infection. Acta Clin Belg (2014) 1.43
Etiological factors and underlying conditions in patients with leucocytoclastic vasculitis. Clin Exp Rheumatol (1997) 1.42
Crohn's disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms. Lancet (2000) 1.42
Human cartilage gp-39+,CD16+ monocytes in peripheral blood and synovium: correlation with joint destruction in rheumatoid arthritis. Arthritis Rheum (2000) 1.39
Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association. J Rheumatol (2000) 1.37
Needle arthroscopy of the knee with synovial biopsy sampling: technical experience in 150 patients. Clin Rheumatol (1999) 1.36
Specific antinuclear antibodies are associated with clinical features in systemic lupus erythematosus. Ann Rheum Dis (2004) 1.32
Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis. Ann Rheum Dis (2005) 1.31
Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease? Ann Rheum Dis (2003) 1.31
A 588-gene microarray analysis of the peripheral blood mononuclear cells of spondyloarthropathy patients. Rheumatology (Oxford) (2002) 1.27
Rheumatoid nodules: differential diagnosis and immunohistological findings. Ann Rheum Dis (1993) 1.23
Juvenile-onset systemic lupus erythematosus: different clinical and serological pattern than adult-onset systemic lupus erythematosus. Ann Rheum Dis (2008) 1.19
The antiperinuclear factor. Clin Exp Rheumatol (1991) 1.18
Psychosocial effects of vitiligo. J Eur Acad Dermatol Venereol (2006) 1.17
Onset of symptoms of rheumatoid arthritis in relation to age, sex and menopausal transition. J Rheumatol (1990) 1.16
The stress protein BiP is overexpressed and is a major B and T cell target in rheumatoid arthritis. Arthritis Rheum (2001) 1.15
Linkage of a polymorphic marker for the type III collagen gene (COL3A1) to atypical autosomal dominant Ehlers-Danlos syndrome type IV in a large Belgian pedigree. Hum Genet (1988) 1.13
Impaired Th1 cytokine production in spondyloarthropathy is restored by anti-TNFalpha. Ann Rheum Dis (2001) 1.13
Diagnostic associations in a large and consecutively identified population positive for anti-SSA and/or anti-SSB: the range of associated diseases differs according to the detailed serotype. Ann Rheum Dis (2002) 1.11
Anti-citrullinated protein/peptide antibodies (ACPA) in rheumatoid arthritis: specificity and relation with rheumatoid factor. Autoimmun Rev (2005) 1.10
CARD15 gene polymorphisms in patients with spondyloarthropathies identify a specific phenotype previously related to Crohn's disease. Ann Rheum Dis (2004) 1.06
Bowel inflammation and the spondyloarthropathies. Rheum Dis Clin North Am (1998) 1.06
Histological evidence that infliximab treatment leads to downregulation of inflammation and tissue remodelling of the synovial membrane in spondyloarthropathy. Ann Rheum Dis (2004) 1.06
Detection and identification of antinuclear antibodies (ANA) in a large and consecutive cohort of serum samples referred for ANA testing. Ann Rheum Dis (2001) 1.05
The effect of TNFalpha blockade on the antinuclear antibody profile in patients with chronic arthritis: biological and clinical implications. Lupus (2005) 1.05
Multicenter validation of recombinant, natural and synthetic antigens used in a single multiparameter assay for the detection of specific anti-nuclear autoantibodies in connective tissue disorders. Clin Exp Rheumatol (1999) 1.02
Differential proteome analysis of normal and osteoarthritic chondrocytes reveals distortion of vimentin network in osteoarthritis. Osteoarthritis Cartilage (2007) 1.01
Detection and identification of antinuclear autoantibodies in the serum of normal blood donors. Clin Exp Rheumatol (1993) 1.01
Synovial detection and autoantibody reactivity of processed citrullinated isoforms of vimentin in inflammatory arthritides. Rheumatology (Oxford) (2008) 1.00
Radiological sacroiliitis, a hallmark of spondylitis, is linked with CARD15 gene polymorphisms in patients with Crohn's disease. Ann Rheum Dis (2004) 0.98
Chemical agents and enzymes used for the extraction of gut lymphocytes influence flow cytometric detection of T cell surface markers. J Immunol Methods (2000) 0.97
Presence of rheumatoid factor and antibodies to citrullinated peptides in systemic lupus erythematosus. Ann Rheum Dis (2005) 0.97
Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: results from the EULAR Scleroderma Trial and Research Group (EUSTAR) database. J Rheumatol (2010) 0.96
Involvement of neurotrophins and their receptors in spondyloarthritis synovitis: relation to inflammation and response to treatment. Ann Rheum Dis (2005) 0.96
Homeostasis of the extracellular matrix of normal and osteoarthritic human articular cartilage chondrocytes in vitro. Osteoarthritis Cartilage (2003) 0.96
Anti-Ro52 reactivity is an independent and additional serum marker in connective tissue disease. Ann Rheum Dis (2002) 0.96
Anti-saccharomyces cerevisiae IgA antibodies are raised in ankylosing spondylitis and undifferentiated spondyloarthropathy. Ann Rheum Dis (2003) 0.95
Colon mucosa of patients both with spondyloarthritis and Crohn's disease is enriched with macrophages expressing the scavenger receptor CD163. Ann Rheum Dis (2004) 0.95
Gut inflammation in psoriatic arthritis: a prospective ileocolonoscopic study. J Rheumatol (1995) 0.94
Flow cytometric analysis of gut mucosal lymphocytes supports an impaired Th1 cytokine profile in spondyloarthropathy. Ann Rheum Dis (2001) 0.94
Reversible changes in serum immunoglobulin galactosylation during the immune response and treatment of inflammatory autoimmune arthritis. Ann Rheum Dis (2008) 0.93
The proportion of Th1 cells, which prevail in gut mucosa, is decreased in inflammatory bowel syndrome. Clin Exp Immunol (2001) 0.93
The combination of microfracture and a cell-free polymer-based implant immersed with autologous serum for cartilage defect coverage. Knee Surg Sports Traumatol Arthrosc (2011) 0.93
Tumour necrosis factor alpha independent disease mechanisms in rheumatoid arthritis: a histopathological study on the effect of infliximab on rheumatoid nodules. Ann Rheum Dis (2004) 0.93
Do all anti-citrullinated protein/peptide antibody tests measure the same? Evaluation of discrepancy between anti-citrullinated protein/peptide antibody tests in patients with and without rheumatoid arthritis. Ann Rheum Dis (2007) 0.92
CARD15 variants determine a disturbed early response of monocytes to adherent-invasive Escherichia coli strain LF82 in Crohn's disease. Int J Immunogenet (2007) 0.92
Technical validation of cDNA based microarray as screening technique to identify candidate genes in synovial tissue biopsy specimens from patients with spondyloarthropathy. Ann Rheum Dis (2004) 0.92
Melanoma inhibitory activity, a biomarker related to chondrocyte anabolism, is reversibly suppressed by proinflammatory cytokines in rheumatoid arthritis. Ann Rheum Dis (2008) 0.92
Focal up-regulation of E-cadherin-catenin complex in inflamed bowel mucosa but reduced expression in ulcer-associated cell lineage. Am J Clin Pathol (2000) 0.92
Proteome characterization of human articular chondrocytes leads to novel insights in the function of small heat-shock proteins in chondrocyte homeostasis. Osteoarthritis Cartilage (2009) 0.91
Polymorphisms in the ficolin 1 gene (FCN1) are associated with susceptibility to the development of rheumatoid arthritis. Rheumatology (Oxford) (2007) 0.91
Joint expedition: linking gut inflammation to arthritis. Mucosal Immunol (2008) 0.91
Enrichment of T cells carrying beta7 integrins in inflamed synovial tissue from patients with early spondyloarthropathy, compared to rheumatoid arthritis. J Rheumatol (1998) 0.91
NKT cells: manipulable managers of joint inflammation. Rheumatology (Oxford) (2007) 0.90
Distinctive activated cellular subsets in colon from patients with Crohn's disease and ulcerative colitis. Scand J Gastroenterol (1998) 0.90
Screening for contact allergy to artificial nails. Contact Dermatitis (2005) 0.89
Churg-Strauss syndrome presenting as polymyositis. Clin Exp Rheumatol (1995) 0.89
Increase in lymphoid follicles and leukocyte adhesion molecules emphasizes a role for the gut in spondyloarthropathy pathogenesis. J Pathol (2002) 0.88
Subclinical gut inflammation in spondyloarthropathy patients is associated with upregulation of the E-cadherin/catenin complex. Ann Rheum Dis (2000) 0.88
Effect of age on prevalence of anticitrullinated protein/peptide antibodies in polyarticular juvenile idiopathic arthritis. Rheumatology (Oxford) (2005) 0.88
Prediction of diagnosis in patients with early arthritis using a combined Kohonen mapping and instance-based evaluation criterion. Artif Intell Med (2004) 0.87
Synovial inflammation does not change in the absence of effective treatment: implications for the use of synovial histopathology as biomarker in early phase clinical trials in rheumatoid arthritis. Ann Rheum Dis (2006) 0.87
A plant-derived glucocorticoid receptor modulator attenuates inflammation without provoking ligand-induced resistance. Ann Rheum Dis (2010) 0.87
Role of lymphotoxin-alpha in cigarette smoke-induced inflammation and lymphoid neogenesis. Eur Respir J (2009) 0.86
Altered expression of alpha E beta 7 integrin on intra-epithelial and lamina propria lymphocytes in patients with Crohn's disease. Acta Gastroenterol Belg (1998) 0.86
X linked agammaglobulinaemia and rheumatoid arthritis. Ann Rheum Dis (2004) 0.86
Sensitivity of the HEp-2000 substrate for the detection of anti-SSA/Ro60 antibodies. Clin Rheumatol (2000) 0.85
A comparative phenotypical analysis of rheumatoid nodules and rheumatoid synovium with special reference to adhesion molecules and activation markers. Ann Rheum Dis (1998) 0.85
The history of injectable biomaterials and the biology of collagen. Aesthetic Plast Surg (1985) 0.85
Exposure to nuclear antigens contributes to the induction of humoral autoimmunity during tumour necrosis factor alpha blockade. Ann Rheum Dis (2008) 0.85
Gut mucosal T cell lines from ankylosing spondylitis patients are enriched with alphaEbeta7 integrin. Clin Exp Rheumatol (2002) 0.84